Rigen Biotech focuses on the molecular diagnosis of thyroid tumors.
Rijing Biosciences has launched thyroid biopsy needles, multi-gene qPCR detection and NGS detection, Thyroscan® thyroid nodule benign and malignant classifier, and targeted surgery for thyroid cancer from preoperative sampling, diagnosis, to postoperative monitoring. Full-process series products such as post-recurrence monitoring provide a variety of solutions for the entire thyroid cancer diagnosis and treatment cycle.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 14, 2022 | Series Unknown | ¥100M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Yinshengtai Capital | — | Series Unknown |